Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?

Jackson BR.

Arch Pathol Lab Med. 2013 Mar;137(3):308-9. doi: 10.5858/arpa.2012-0241-ED. Epub 2012 Jul 16. No abstract available.

PMID:
22799565
2.

Early detection of prostate cancer.

Taneja SS.

Urol Clin North Am. 2014 May;41(2):xi-xii. doi: 10.1016/j.ucl.2014.03.002. No abstract available.

PMID:
24725495
3.

Alternative prostate cancer screening strategies.

Labrecque M, Aprikian A.

Ann Intern Med. 2013 May 21;158(10):778. doi: 10.7326/0003-4819-158-10-201305210-00019. No abstract available.

PMID:
23689773
4.

Alternative prostate cancer screening strategies--in response.

Gulati R, Etzioni R.

Ann Intern Med. 2013 May 21;158(10):778-9. doi: 10.7326/0003-4819-158-10-201305210-00020. No abstract available.

PMID:
23689774
5.

Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50".

Andriole GL, Kibel AS.

Cancer. 2011 Mar 15;117(6):1110-2. doi: 10.1002/cncr.25559. Epub 2010 Oct 19. No abstract available.

PMID:
20960524
6.

Summaries for patients. Screening smarter, not harder, for prostate cancer.

[No authors listed]

Ann Intern Med. 2013 Feb 5;158(3):I-30. doi: 10.7326/0003-4819-158-3-201302050-00001. No abstract available.

PMID:
23381056
7.

[Does a low PSA at 60 years old exclude the risk of developing prostate carcinoma?].

Zürcher S.

Rev Med Suisse. 2014 Jun 11;10(434):1316. French. No abstract available.

PMID:
25073308
8.

Prostate cancer screening.

Sikaris K.

Pathology. 2012 Feb;44(2):99-109. doi: 10.1097/PAT.0b013e32834fbb2c. Review.

PMID:
22198258
9.

The new data on prostate cancer screening: what should we do now?

Gilligan T.

Cleve Clin J Med. 2009 Aug;76(8):446-8. doi: 10.3949/ccjm.76a.09079. No abstract available.

PMID:
19652037
10.

Informed prostate cancer risk-adjusted testing: a new paradigm.

Stricker PD, Frydenberg M, Kneebone A, Chopra S.

BJU Int. 2012 Dec;110 Suppl 4:30-4. doi: 10.1111/j.1464-410X.2012.11621.x. Review.

PMID:
23194122
11.
12.

Probability, uncertainty, and prostate cancer.

Concato J.

Ann Intern Med. 2013 Feb 5;158(3):211-2. doi: 10.7326/0003-4819-158-3-201302050-00012. No abstract available.

PMID:
23381041
13.

Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.

Mian BM.

Urol Oncol. 2010 May-Jun;28(3):233-6. doi: 10.1016/j.urolonc.2009.11.011. Epub 2010 Jan 25. No abstract available.

PMID:
20097584
14.

Prostate cancer screening "reloaded".

Gomella LG.

Can J Urol. 2010 Apr;17(2):5057. No abstract available.

PMID:
20398441
15.

Prostate-specific antigen screening for prostate cancer in older men in the United States of America.

Black A, Berg CD.

Gerontology. 2012;58(4):331-6. doi: 10.1159/000334242. Epub 2012 Feb 16.

PMID:
22343605
16.

Screening for prostate cancer.

Croswell J, Shin YR.

Am Fam Physician. 2013 Feb 15;87(4):283-4. No abstract available.

PMID:
23418805
17.

Prostate specific antigen and screening for early prostate cancer.

Davidson P.

N Z Med J. 2001 Apr 13;114(1129):150. No abstract available.

PMID:
11400919
18.

Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.

Braillon A, Dubois G.

J Natl Cancer Inst. 2012 May 16;104(10):793; author reply 793-4. doi: 10.1093/jnci/djs205. Epub 2012 Apr 5. No abstract available.

PMID:
22491229
19.

Landmarks in prostate cancer screening.

Schröder FH.

BJU Int. 2012 Oct;110 Suppl 1:3-7. doi: 10.1111/j.1464-410X.2012.011428.x. Review.

PMID:
23046034
20.

Screening for prostate cancer remains controversial.

Neal DE, Donovan JL, Martin RM, Hamdy FC.

Lancet. 2009 Oct 31;374(9700):1482-3. doi: 10.1016/S0140-6736(09)61085-0. Epub 2009 Aug 5. Review. No abstract available.

PMID:
19664817

Supplemental Content

Support Center